UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) October 28, 2014

 

NEPHROS, INC.

 
(Exact name of registrant as specified in its charter)

 

 

Delaware

 (State or other jurisdiction of incorporation)

 

  001-32288   13-3971809  
  (Commission File Number)   (IRS Employer ID Number)  
         
  41 Grand Avenue, River Edge, New Jersey   07661  
   (Address of principal executive offices)   (Zip Code)  

 

 

Registrant's telephone number, including area code (201) 343-5202

 

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act   (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

 
 

 

 

Item 8.01. Other Events.

 

On October 28, 2014, Nephros, Inc. issued a press release announcing that it received 510(k) clearance from the Food and Drug Administration to market its DSU-H and SSU-H Ultrafilters for use in the hospital setting. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

 

Item 9.01. Financial Statements and Exhibits.

 

 

(d)           Exhibits

   
  Exhibit No.

Description 

     
  99.1 Press Release dated October 28, 2014.

 

 

 
 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

         

    Nephros, Inc.
     
  By: /s/ John C. Houghton
Dated:  October 28, 2014   John C. Houghton
   

President, Chief Executive Officer

and Acting Chief Financial Officer